Broderick Brian C boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,968 shares of the company's stock after buying an additional 1,457 shares during the quarter. Johnson & Johnson makes up about 3.5% of Broderick Brian C's investment portfolio, making the stock its 8th biggest holding. Broderick Brian C's holdings in Johnson & Johnson were worth $11,266,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Goodman Advisory Group LLC acquired a new position in Johnson & Johnson in the second quarter valued at approximately $39,000. Cowa LLC acquired a new position in Johnson & Johnson in the third quarter valued at approximately $58,000. First Bank & Trust boosted its stake in Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company's stock valued at $67,000 after acquiring an additional 156 shares during the period. Adirondack Retirement Specialists Inc. acquired a new position in Johnson & Johnson in the third quarter valued at approximately $67,000. Finally, Heritage Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $84,000. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

NYSE JNJ opened at $164.61 on Monday. The stock has a market capitalization of $430.37 billion, a P/E ratio of 24.42, a P/E/G ratio of 2.83 and a beta of 0.54. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The business's fifty day moving average is $174.35 and its two-hundred day moving average is $170.54. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.75%. Johnson & Johnson's dividend payout ratio is currently 67.06%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business's stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares of the company's stock, valued at approximately $6,431,835.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business's stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares of the company's stock, valued at approximately $6,431,835.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Ashley Mcevoy sold 73,323 shares of the business's stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the sale, the executive vice president now directly owns 41,813 shares in the company, valued at $7,336,927.11. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 198,365 shares of company stock valued at $34,927,325. Corporate insiders own 0.35% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Raymond James reduced their price objective on Johnson & Johnson from $192.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, October 19th. Sanford C. Bernstein reduced their price objective on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Credit Suisse Group assumed coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a "neutral" rating and a $170.00 price objective for the company. Finally, Bank of America reduced their price objective on Johnson & Johnson from $185.00 to $178.00 and set a "neutral" rating for the company in a research report on Friday, October 14th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $185.23.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets.

See Also

• Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
• Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
• MarketBeat Week in Review – 1/30 – 2/3
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.